Anti-PD-1 therapy resulted in treatment discontinuation in 30 (15.8%) of patients, with the most common etiology being pneumonitis in 6 patients (20.0%), colitis in 5 patients (16.7%), and hepatitis in 5 patients (16.7%). Here, PDCD1 is linked to hepatitis A virus infection.